Cationic Lipid Nanoparticles for Nucleic Acid Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid delivery systems face challenges such as susceptibility to nuclease digestion in plasma and limited intracellular access, necessitating improved cationic lipids and lipid nanoparticles for effective protection and delivery of therapeutic agents like oligonucleotides.
Innovation Solution
Development of novel cationic lipids and lipid nanoparticles, combined with neutral lipids, cholesterol, and polymer conjugated lipids, to form stable nanoparticles that protect nucleic acids from degradation and facilitate intracellular delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If free nucleic acids are used for delivery, then the delivery system is simple, but the nucleic acids are susceptible to nuclease digestion in plasma
Solution Approach 1:
The patent uses composite lipid nanoparticles comprising cationic lipids, neutral lipids, cholesterol, and polymer conjugated lipids to form a protective载体 that encapsulates and protects nucleic acids from nuclease digestion in plasma, resolving the contradiction between system simplicity and nucleic acid stability
Solution Approach 2:
The lipid nanoparticle acts as an intermediary carrier between the nucleic acid and the target cell, protecting the nucleic acid from degradation while facilitating delivery, thus resolving the stability issue without significantly increasing complexity
2Device complexity
If free nucleic acids are used for delivery, then the delivery system is simple, but the nucleic acids have limited ability to gain access to intracellular compartments
Solution Approach 1:
The composite lipid nanoparticle structure with cationic lipids facilitates endocytosis and intracellular delivery of nucleic acids to appropriate compartments, overcoming the limited intracellular access issue while maintaining relative simplicity
Solution Approach 2:
The patent modifies the physical and chemical parameters of the delivery system by using lipid nanoparticles with specific composition and size characteristics, enabling enhanced intracellular access and delivery efficiency
3Reliability
If conventional cationic lipids are used, then the lipid nanoparticles can protect nucleic acids, but the therapeutic index is insufficient with unacceptable toxicity
Solution Approach 1:
The patent optimizes parameters of the cationic lipids including charge density, fatty acid composition, and molecular structure to enhance nucleic acid protection while reducing cellular toxicity and improving therapeutic index
Solution Approach 2:
The use of composite lipid nanoparticles with multiple lipid components (cationic, neutral, cholesterol, polymer conjugated) provides synergistic effects that enhance protection while improving tolerability and safety profile
Data Source
AI summary
Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein a, b, c, d, G1, G2, L1, L2, R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8 and X are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, nanoparticles comprising the compounds and methods for their use and preparation are also provided.